B6-hIL33 Mouse
Product Name
B6-hIL33 Mouse
Product ID
C001722
Strain Name
C57BL/6NCya-Il33em1(hIL33)/Cya
Backgroud
C57BL/6NCya
When using this mouse strain in a publication, please cite “B6-hIL33 Mouse (Catalog C001722) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
Gene Name
Gene Alias
DVS27, IL1F11, NF-HEV, NFEHEV, C9orf26
NCBI ID
Chromosome
Chr 9
MGI ID
Datasheet
Strain Description
IL33 encodes interleukin-33 (IL-33), a member of the IL-1 cytokine family that operates as a crucial "alarmin" molecule within the immune system [1]. Released by epithelial and endothelial cells, as well as other cell types, upon cellular damage or stress, IL-33 signals through its receptor, the IL1RL1/ST2 heterodimer, expressed on various immune cells, including Th2 cells, mast cells, basophils, eosinophils, and innate lymphoid cells type 2 (ILC2s). Receptor engagement activates downstream signaling pathways, notably NF-κB and MAPK, culminating in the production of type 2 cytokines such as IL-4, IL-5, and IL-13, thereby promoting Th2 cell differentiation and orchestrating type 2 immune responses critical for defense against helminths and in allergic inflammation [1-2]. Constitutive expression of IL-33 in barrier tissues positions it as a sentinel, contributing to tissue homeostasis and rapidly responding to environmental insults [3]. Aberrant expression and signaling of IL-33 have been strongly implicated in the pathogenesis of a spectrum of inflammatory conditions, including asthma, atopic dermatitis, allergic rhinitis, and inflammatory bowel disease, highlighting its significance as a potential therapeutic target in these disorders [4].
The B6-hIL33 mouse is a humanized model constructed by replacing the sequence of the mouse Il33 gene in situ with the corresponding sequence from the human IL33 gene. The B6-hIL33 mice can be used for studies on asthma, atopic dermatitis, allergic rhinitis, inflammatory bowel disease, and other inflammatory disorders, as well as for IL33-targeted drug development.
Reference
Shakerian L, Kolahdooz H, Garousi M, Keyvani V, Kamal Kheder R, Abdulsattar Faraj T, Yazdanpanah E, Esmaeili SA. IL-33/ST2 axis in autoimmune disease. Cytokine. 2022 Oct;158:156015.
Kudo-Saito C, Miyamoto T, Imazeki H, Shoji H, Aoki K, Boku N. IL33 Is a Key Driver of Treatment Resistance of Cancer. Cancer Res. 2020 May 15;80(10):1981-1990.
Zhou Z, Yan F, Liu O. Interleukin (IL)-33: an orchestrator of immunity from host defence to tissue homeostasis. Clin Transl Immunology. 2020 Jun 17;9(6):e1146.
Cayrol C. IL-33, an Alarmin of the IL-1 Family Involved in Allergic and Non Allergic Inflammation: Focus on the Mechanisms of Regulation of Its Activity. Cells. 2021 Dec 30;11(1):107.
Strain Strategy
Figure 1. Gene editing strategy of B6-hIL33 Mice. The sequences from ATG start codon to TAA stop codon of the endogenous mouse Il33 gene were replaced with the sequences from ATG start codon to TAG stop codon of the human IL33 gene.
Application Area
IL33-targeted drug screening, development, and evaluation;
Research on the pathological mechanisms and therapeutic approaches of asthma, atopic dermatitis, allergic rhinitis, and inflammatory bowel disease;
Research on other inflammatory disorders.
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.